From these data, we conclude that downregulation of FBXO11 is observed in secondary and tAML patient samples, and patients with low FBXO11 expression have a higher incidence of abnormal EZH2 splicing events that are observed in SRSF2mt AML. Here, EZH2 is linked to acute myeloid leukemia.